Analysts' Evaluation and Target Price Changes for AVITA Medical

Summary

Six analysts have mixed opinions on AVITA Medical, with a 12-month average target price of $21.67, down 6.47% from the previous $23.17. Key analysts include Jason Kolbert from D. Boral Capital with a ‘buy’ rating at $22.00 and Brooks O’Neil from Lake Street lowering the target to $14.00. AVITA Medical’s Recell system is gaining recognition in the U.S., with a reported revenue growth rate of 29.67%. The company faces challenges such as high debt-to-equity ratio and negative returns on equity and assets.Benzinga

Impact Analysis

The event is at the company level, as it focuses on AVITA Medical’s stock target price adjustments by analysts. The mixed opinions reflect both optimism regarding AVITA Medical’s Recell system and caution due to financial challenges such as high debt levels and negative returns.Benzinga+ 3 First-order effects include potential stock price volatility as investor sentiment shifts based on analyst ratings and company performance. Second-order effects could involve broader impacts on investor confidence in AVITA Medical’s ability to overcome financial obstacles. Investment opportunities might lie in short-term trading strategies based on analyst ratings or long-term positions considering the company’s growth prospects in the U.S. market.Trading View+ 2